In this video, Doris Hansen, MD, Moffitt Cancer Center, Tampa, FL, briefly discusses strategies to optimize the efficacy of CAR-T therapy for patients with multiple myeloma in the real-world setting. Dr Hansen also highlights the importance of further investigating the optimal sequencing of BCMA-targeted agents to improve patient outcome. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
